$120.17
0.86% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Neurocrine Biosciences, Inc. Stock price

$120.17
-25.46 17.48% 1M
-12.08 9.13% 6M
-11.59 8.80% YTD
+10.00 9.08% 1Y
+24.30 25.35% 3Y
+21.17 21.38% 5Y
+104.05 645.47% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-1.04 0.86%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $12.13b
Enterprise Value $11.39b
P/E (TTM) P/E ratio 36.30
EV/FCF (TTM) EV/FCF 23.02
EV/Sales (TTM) EV/Sales 5.37
P/S ratio (TTM) P/S ratio 5.73
P/B ratio (TTM) P/B ratio 4.83
Revenue growth (TTM) Revenue growth 26.69%
Revenue (TTM) Revenue $2.12b
EBIT (operating result TTM) EBIT $544.70m
Free Cash Flow (TTM) Free Cash Flow $494.60m
Cash position $1.04b
EPS (TTM) EPS $3.31
P/E forward 24.41
P/S forward 5.21
EV/Sales forward 4.89
Short interest 2.65%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

24x Buy
86%
4x Hold
14%

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,120 2,120
27% 27%
100%
- Direct Costs 58 58
15% 15%
3%
2,062 2,062
27% 27%
97%
- Selling and Administrative Expenses 884 884
9% 9%
42%
- Research and Development Expense 609 609
23% 23%
29%
569 569
81% 81%
27%
- Depreciation and Amortization 25 25
34% 34%
1%
EBIT (Operating Income) EBIT 545 545
84% 84%
26%
Net Profit 339 339
92% 92%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine'), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as announced on 2...
Neutral
The Motley Fool
8 days ago
The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.
Positive
Seeking Alpha
10 days ago
Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indications like Alzheimer's Disease. There are several other shots on goal in targeting the Schizophrenia patient populations using luvadaxistat and others. The global Schizophrenia Drugs Market is forecast...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Gorman
Employees 1,400
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today